← Back to Search

Vaccine

Tdap Vaccine for Alzheimer's Disease

Phase 1 & 2

Waitlist Available

Led By Coad T Dow, MD

Research Sponsored by Mindful Diagnostics and Therapeutics, LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up start of study and 6 months

Awards & highlights

Study Summary

This trial will test if the Tdap vaccine can help protect against Alzheimer's disease by looking at changes in biomarkers before and after vaccination.

Who is the study for?

This trial is for individuals who can consent, have a competent immune system, scored 17 or higher on the SAGE test, and haven't had the Tdap vaccine in the last 10 years. It's not for those allergic to Tdap components, with compromised immunity, recently vaccinated with Tdap, or scoring below 17 on SAGE.Check my eligibility

What is being tested?

The study investigates if the Tdap vaccine affects biomarkers associated with Alzheimer's Disease. Participants will have blood tests to measure specific proteins related to Alzheimer's before and six months after receiving the vaccine.See study design

What are the potential side effects?

While this summary doesn't specify side effects of Tdap in this context, common reactions include pain at injection site, mild fever, fatigue and headache.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ start of study and 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~start of study and 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and start of study and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Plasma Amyloid

Change in Plasma Tau

Secondary outcome measures

B. pertussis IgG

Presence of B. pertussis

Trial Design

1Treatment groups

Experimental Treatment

Group I: TdapExperimental Treatment1 Intervention

Open label study, no placebo comparator

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Mindful Diagnostics and Therapeutics, LLCLead Sponsor

1 Previous Clinical Trials

49 Total Patients Enrolled

Infectious Disease Society of AmericaUNKNOWN

Coad T Dow, MDPrincipal InvestigatorMindful Diagnostics and Therapeutics

Media Library

Tdap Vaccine (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05183516 — Phase 1 & 2

Alzheimer's Disease Research Study Groups: Tdap

Alzheimer's Disease Clinical Trial 2023: Tdap Vaccine Highlights & Side Effects. Trial Name: NCT05183516 — Phase 1 & 2

Tdap Vaccine (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05183516 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research still accept participants?

"Confirmed, this particular trial is no longer accepting candidates as of August 22nd 2022; the initial posting was on May 1st 2023. Nonetheless, 546 other medical studies are currently open to participants at this time."

Answered by AI

Is the participant pool for this research limited to those over 20 years old?

"To be eligible to participate in this trial, patients must range between 50 and 80 years old. Meanwhile, there are 23 studies available for minors under 18 as well 536 trials catered towards individuals aged 65 or more."

Answered by AI

To whom is access to this research study available?

"This trial is searching for 50 participants aged between 50 and 80 that have been diagnosed with Alzheimer's. Additionally, they must demonstrate immunocompetence, the capacity to provide informed consent, no Tdap inoculation in the past decade and a SAGE test result of 17 or higher."

Answered by AI

Recent research and studies

The Journals of Gerontology: Series AJournal

Lower Risk for Dementia Following Adult Tetanus, Diphtheria, and Pertussis (tdap) Vaccination

Scherrer, Jeffrey F, Joanne Salas, Timothy L Wiemken, Christine Jacobs, John E Morley, and Daniel F Hoft. 2021. “Lower Risk for Dementia Following Adult Tetanus, Diphtheria, and Pertussis (tdap) Vaccination”. Edited by Lewis Lipsitz. The Journals of Gerontology: Series A. Oxford University Press (OUP). doi:10.1093/gerona/glab115.

ImmunobiologyJournal

The Pertussis Hypothesis: Bordetella Pertussis Colonization in the Pathogenesis of Alzheimer’s Disease

Rubin, Keith, and Steven Glazer. 2017. “The Pertussis Hypothesis: Bordetella Pertussis Colonization in the Pathogenesis of Alzheimer’s Disease”. Immunobiology. Elsevier BV. doi:10.1016/j.imbio.2016.09.017.

Molecular NeurodegenerationJournal

A Blood-based Diagnostic Test Incorporating Plasma Aβ42/40 Ratio, Apoe Proteotype, and Age Accurately Identifies Brain Amyloid Status: Findings from a Multi Cohort Validity Analysis

West, Tim, Kristopher M. Kirmess, Matthew R. Meyer, Mary S. Holubasch, Stephanie S. Knapik, Yan Hu, John H. Contois, et al.. 2021. “A Blood-based Diagnostic Test Incorporating Plasma Aβ42/40 Ratio, Apoe Proteotype, and Age Accurately Identifies Brain Amyloid Status: Findings from a Multi Cohort Validity Analysis”. Molecular Neurodegeneration. Springer Science and Business Media LLC. doi:10.1186/s13024-021-00451-6.

Journal of the American Geriatrics SocietyJournal